Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1429884 | 1.00 | BACE1 (0.77) | BACE1 | |
| SCHEMBL1170699 | 0.93 | BACE1 (0.76) | BACE1 | |
| SCHEMBL1429566 | 0.93 | BACE1 (0.76) | BACE1 | |
| SCHEMBL1430122 | 0.92 | BACE1 (0.83) | BACE1 | |
| SCHEMBL1171115 | 0.92 | BACE1 (0.83) | BACE1 | |
| SCHEMBL1170526 | 0.92 | BACE1 (0.75) | BACE1 | |
| SCHEMBL1429553 | 0.92 | BACE1 (0.75) | BACE1 | |
| SCHEMBL1170847 | 0.92 | BACE1 (0.65) | BACE1 | |
| SCHEMBL1429888 | 0.91 | BACE1 (0.77) | BACE1 | |
| SCHEMBL1171014 | 0.91 | BACE1 (0.77) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300484-B1 | NOVEL CLASS OF SPIRO PIPERIDINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PFIZER (US) | 2011-12-14 | — | — | EP | claimed |
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | PFIZER, INC. | 2011-02-24 | — | — | US | claimed |
| EP-2300484-B1 | NOVEL CLASS OF SPIRO PIPERIDINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PFIZER (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | PFIZER, INC. | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | SNCA, PARK7, HTT | BACE1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.